Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | HTR6 | P50406 | 8/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ACLY | P53396 | 1/20 | 0.45 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6866228 | 0.96 | HTR6 (0.57) | RECQLHTR6POLBL3MBTL1HDAC1 | |
| SCHEMBL6860277 | 0.93 | RECQL (0.58) | RECQLHTR6POLBL3MBTL1HDAC1 | |
| SCHEMBL6860250 | 0.88 | HTR6 (0.47) | RECQLHTR6POLBL3MBTL1HDAC1 | |
| SCHEMBL6866858 | 0.86 | HTR6 (0.47) | RECQLHTR6POLBL3MBTL1HDAC1 | |
| SCHEMBL6864332 | 0.86 | RECQL (0.73) | RECQLHTR6HDAC1HDAC6HDAC3 | |
| SCHEMBL6866844 | 0.85 | HTR6 (0.47) | RECQLHTR6POLBL3MBTL1HDAC1 | |
| SCHEMBL17927513 | 0.84 | HTR6 (0.69) | RECQLHTR6POLBL3MBTL1HDAC1 | |
| SCHEMBL5716666 | 0.83 | RECQL (0.51) | RECQLHTR6POLBL3MBTL1HDAC1 | |
| SCHEMBL5716696 | 0.83 | HDAC3 (0.47) | RECQLHTR6POLBL3MBTL1HDAC1 | |
| SCHEMBL6865379 | 0.83 | HDAC3 (0.66) | HTR6POLBL3MBTL1HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812243-B2 | AS TYROSINE KINASE INHIBITORS; FOR THERARPY OF TUMORS, ARTERIOSCLEROSIS, RESTENOSIS AFTER BALLOON ANGIOPLASTY, ARTHRITIS AND FIBROTIC DISEASES | ZENTARIS AG (DE) | 2004-11-02 | — | — | US | disclosed |
| US-20030008898-A1 | Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation | ZENTARIS AG (DE) | 2003-01-09 | — | — | US | disclosed |
| EP-1109785-B1 | INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MALIGNANT AND OTHER DISEASES CAUSED BY PATHOLOGICAL CELL PROLIFERATION | ZENTARIS AG (DE) | 2003-01-02 | — | — | EP | disclosed |
| US-6407102-B1 | TYROSINE KINASE AND PLATELET-DERIVED GROWTH FACTOR INHIBITORS; ANTICARCINOGENIC, ANTITUMOR, ANTIARTHRITIC AND ANTIPROLIFERATIVE AGENTS; RESTENOSIS, ARTERIOSCLEROSIS | ZENTARIS AG (DE) | 2002-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008898-A1 | Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation | MKI67, IDO1, CCNI | RECQL 3640/4885HTR6 265/4885POLB 2321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.